^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PD-L1 inhibitor

    Related drugs:
    15h
    QUILT 3.064: QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers (clinicaltrials.gov)
    P1, N=16, Completed, ImmunityBio, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PD-L1.t-haNK
    16h
    A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=63, Completed, Incyte Corporation | Recruiting --> Completed
    Trial completion
    |
    INCB99280
    17h
    PHASE III STUDY WITH ATEZOLIZUMAB VERSUS PLACEBO IN MALIGNANT PLEURAL MESOTHELIOMAnPATIENTS AFTER PLEURECTOMY/DECORTICATION (2024-519286-21-00)
    P2/3, N=90, Recruiting, G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Tecentriq (atezolizumab)
    17h
    INFINITY: TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC. (clinicaltrials.gov)
    P2, N=31, Active, not recruiting, Gruppo Oncologico del Nord-Ovest | Not yet recruiting --> Active, not recruiting
    Enrollment closed • MSI-H
    |
    MSI-H/dMMR
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    1d
    Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC. (PubMed, Br J Cancer)
    Ceralasertib plus durvalumab was tolerated and associated with antitumour activity in advanced/metastatic NSCLC and HNSCC.
    P1 data • Journal
    |
    ATR (Ataxia telangiectasia and Rad3-related protein)
    |
    Imfinzi (durvalumab) • ceralasertib (AZD6738)
    1d
    Photochemical enhancement of PD-L1-SAP immunotoxin efficacy in non-small cell lung cancer cell lines. (PubMed, Front Immunol)
    Importantly, co-treatment with the immune checkpoint inhibitor atezolizumab (Tecentriq®) reduced PCI efficacy in PD-L1^high^ cells, underscoring the importance of receptor accessibility. These findings demonstrate that PCI enhances delivery and activity of PD-L1-targeted biologics and may help overcome resistance mechanisms. Overall, PCI expands the therapeutic window of PD-L1-targeted immunotoxins and may complement current immunotherapies, supporting further preclinical evaluation in NSCLC.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab)
    1d
    MS100070_0176: Avelumab Program Rollover Study (clinicaltrials.gov)
    P3, N=205, Active, not recruiting, EMD Serono Research & Development Institute, Inc. | Trial completion date: Feb 2027 --> Aug 2026 | Trial primary completion date: Feb 2027 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    Bavencio (avelumab)
    2d
    TRITON: A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (clinicaltrials.gov)
    P2, N=100, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting | Phase classification: P3 --> P2 | N=280 --> 100 | Trial completion date: Mar 2031 --> Dec 2027 | Trial primary completion date: Aug 2027 --> Dec 2026
    Enrollment closed • Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    KRAS mutation • EGFR mutation • STK11 mutation • ALK fusion • KEAP1 mutation
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • pemetrexed
    3d
    HAIBrave-001: HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma (NCT06737913)
    P2, N=76, Recruiting, Sun Yat-sen University | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2027 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • AiRuiLi (adebrelimab)
    4d
    GIM25-CAPT: A Phase II trial of atezolizumab plus CArboplatin plus nab-Paclitaxel as first-line Therapy in metastatic triple-negative PD-L1 positive breast cancer patients (2024-519514-31-00)
    P1/2, N=104, Recruiting, Consorzio Oncotech | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 negative • HR negative • HER-2 negative + HR negative
    |
    VENTANA PD-L1 (SP142) Assay
    |
    Tecentriq (atezolizumab) • carboplatin • albumin-bound paclitaxel
    4d
    ASPIRE: Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC (clinicaltrials.gov)
    P2, N=90, Recruiting, Fundacion Clinic per a la Recerca Biomédica | Not yet recruiting --> Recruiting
    Enrollment open
    |
    AFP (Alpha-fetoprotein) • CD4 (CD4 Molecule)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)